Urate as a predictor of the rate of clinical decline in Parkinson disease.

ABSTRACT:

Background

The risk of Parkinson disease (PD) and its rate of progression may decline with increasing concentration of blood urate, a major antioxidant.

Objective

To determine whether serum and cerebrospinal fluid concentrations of urate predict clinical progression in patients with PD.

Design, setting, and participants

Eight hundred subjects with early PD enrolled in the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP) trial. The pretreatment urate concentration was measured in serum for 774 subjects and in cerebrospinal fluid for 713 subjects.

Main outcome measures

Treatment-, age-, and sex-adjusted hazard ratios (HRs) for clinical disability requiring levodopa therapy, the prespecified primary end point of the original DATATOP trial.

SUBMITTER: Ascherio A 

PROVIDER: S-EPMC2795011 | biostudies-literature | 2009 Dec

REPOSITORIES: biostudies-literature